nach oben

Gynäkologische Endokrinologie

Erschienen in:

01.05.2015 | Arzneimitteltherapie

Selektive Östrogenrezeptormodulatoren (SERM)

verfasst von: PD Dr. med. Petra Stute, Martin Birkhäuser

Erschienen in: Gynäkologische Endokrinologie | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Selektive Östrogenrezeptormodulatoren (SERM) bilden eine heterogene Klasse nichtsteroidaler Substanzen, die nicht nur wie Östrogene, sondern auch als Antiöstrogene wirken.

Indikationen

Die Indikationsgebiete reichen substanzspezifisch von der Therapie des Mammakarzinoms (Tamoxifen) oder der Osteoporose (Raloxifen, Bazedoxifen) bis hin zur Therapie des unerfüllten Kinderwunschs (Clomifen). Daneben sind Tamoxifen und Raloxifen im Ausland z. T. für die Prävention des Mammakarzinoms bei Frauen mit erhöhtem Mammakarzinomrisiko zugelassen. Bei Frauen mit vasomotorischen Symptomen und gleichzeitig erhöhtem Osteoporose- und Mammakarzinomrisiko wird die vor der Einführung stehende Kombination aus Bazedoxifen und konjugierten Östrogenen eine interessante zusätzliche therapeutische Möglichkeit bieten. Vielversprechend ist der 2013 von der U.S. Food and Drug Administration zugelassene SERM Ospemifen zur Therapie der Dyspareunie bei vulvovaginaler Atrophie in der Postmenopause.

Rollerova E, Urbancikova M (2000) Intracellular estrogen receptors, their characterization and function (Review). Endocr Regul 34(4):203–218PubMed

McDonnell DP (2005) The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. Clin Cancer Res 11(2 Pt 2):871s–877sPubMed

McInerney EM, Weis KE, Sun J, Mosselman S, Katzenellenbogen BS (1998) Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology 139(11):4513–4522PubMed

Birkhäuser M (2012) Selektive Oestrogen-Rezeptormodulatoren (SERMs) zur Prävention und Therapie der postmenopausalen Osteoporose. Ther Umsch 69(1):63–172

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7):637–645CrossRefPubMed

Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33(4):522–532CrossRefPubMed

Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR, Continuing Outcomes Relevant to Evista I (2005) Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 20(9):1514–1524. DOI 10.1359/JBMR.050509CrossRefPubMed

Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR, Investigators C (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96(23):1751–1761. DOI 10.1093/jnci/djh319CrossRefPubMed

Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK, Raloxifene Use for The Heart Trial I (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355(2):125–137. DOI 10.1056/NEJMoa062462CrossRefPubMed

10.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, National Surgical Adjuvant Breast and Bowel Project (NSABP) (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727–2741. DOI 10.1001/jama.295.23.joc60074CrossRefPubMed

11.

Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD (2006) Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 17(2):313–316. DOI 10.1007/s00198-005-2030-1CrossRefPubMed

12.

Kanis JA, Johnell O, Black DM, Downs RW Jr, Sarkar S, Fuerst T, Secrest RJ, Pavo I (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33(3):293–300CrossRefPubMed

13.

Kanis JA, Johansson H, Oden A, McCloskey EV (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 47(4):729–735. DOI 10.1016/j.bone.2010.06.009CrossRefPubMed

14.

Qu Y, Wong M, Thiebaud D, Stock JL (2005) The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial. Curr Med Res Opin 21(12):1955–1959. DOI 10.1185/030079905X75032CrossRefPubMed

15.

Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD (2002) Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 162(10):1140–1143CrossRefPubMed

16.

Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65(2):125–134CrossRefPubMed

17.

Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D (2009) Raloxifene and risk for stroke based on the framingham stroke risk score. Am J Med 122(8):754–761. DOI 10.1016/j.amjmed.2009.01.033CrossRefPubMed

18.

Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD (2008) Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23(4):525–535. DOI 10.1359/jbmr.071206CrossRefPubMed

19.

Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23(12):1923–1934. DOI 10.1359/jbmr.080710CrossRefPubMed

20.

Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44(6):1049–1054. DOI 10.1016/j.bone.2009.02.014CrossRefPubMed

21.

Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjaerg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD, Bazedoxifene Study G (2012) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23(1):351–363. DOI 10.1007/s00198-011-1691-1CrossRefPubMed

22.

Chines AA, Komm BS (2009) Bazedoxifene acetate: a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Drugs Today 45(7):507–520. DOI 10.1358/dot.2009.45.7.1395293PubMed

23.

Christiansen C, Chesnut CH 3rd, Adachi JD, Brown JP, Fernandes CE, Kung AW, Palacios S, Levine AB, Chines AA, Constantine GD (2010) Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord 11:130. DOI 10.1186/1471-2474-11-130CrossRefPubMedCentralPubMed

24.

de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB, Codreanu C, Kelepouris N, Brown JP (2011) Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 22(2):567–576. DOI 10.1007/s00198-010-1302-6CrossRefPubMed

25.

Komm BS, Chines AA (2012) An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis. Maturitas 71(3):221–226. DOI 10.1016/j.maturitas.2011.11.018CrossRefPubMed

26.

Komm BS, Mirkin S (2012) Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy. Int J Womens Health 4:129–140. DOI 10.2147/IJWH.S 29346CrossRefPubMedCentralPubMed

27.

Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G (2009) Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 92(3):1045–1052. DOI 10.1016/j.fertnstert.2009.02.093CrossRefPubMed

28.

Lobo RA, Pinkerton JV, Gass ML, Dorin MH, Ronkin S, Pickar JH, Constantine G (2009) Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 92(3):1025–1038. DOI 10.1016/j.fertnstert.2009.03.113CrossRefPubMed

29.

Mirkin S, Komm BS, Pan K, Chines AA (2013) Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric 16(3):338–346. DOI 10.3109/13697137.2012.717994CrossRefPubMed

30.

Pickar JH, Yeh IT, Bachmann G, Speroff L (2009) Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 92(3):1018–1024. DOI 10.1016/j.fertnstert.2009.05.094CrossRefPubMed

31.

Pinkerton JV, Pickar JH, Racketa J, Mirkin S (2012) Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention. Climacteric 15(5):411–418. DOI 10.3109/13697137.2012.696289CrossRefPubMed

32.

Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH (2009) Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 16(6):1116–1124. DOI 10.1097/gme.0b013e3181a7df0dCrossRefPubMed

33.

Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH (2009) Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 63(4):329–335. DOI 10.1016/j.maturitas.2009.06.006CrossRefPubMed

34.

Pinkerton JV, Harvey JA, Pan K, Thompson JR, Ryan KA, Chines AA, Mirkin S (2013) Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol 121(5):959–968. DOI 10.1097/AOG.0b013e31828c5974CrossRefPubMed

35.

DeGregorio MW, Zerbe RL, Wurz GT (2014) Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Steroids. DOI 10.1016/j.steroids.2014.07.012

36.

Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU (2002) Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 43(3):207–214CrossRefPubMed

37.

DeGregorio MW, Wurz GT, Taras TL, Erkkola RU, Halonen KH, Huupponen RK (2000) Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. Eur J Clin Pharmacol 56(6–7):469–475CrossRefPubMed

38.

Koskimies P, Katila K, Lammintausta R, Aaltonen AM, Vuorinen J, Saarni O, Scheinin M (2013) Oral bioavailability of ospemifene improves with food intake. Int J Clin Pharmacol Ther 51(10):787–794. DOI 10.5414/CP201873CrossRefPubMed

39.

Koskimies P, Turunen J, Lammintausta R, Scheinin M (2013) Single-dose and steady-state pharmacokinetics of ospemifene, a selective estrogen receptor modulator, in postmenopausal women. Int J Clin Pharmacol Ther 51(11):861–867. DOI 10.5414/CP201925CrossRefPubMed

40.

Tolonen A, Koskimies P, Turpeinen M, Uusitalo J, Lammintausta R, Pelkonen O (2013) Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact 28(3):153–161. DOI 10.1515/dmdi-2013-0016CrossRefPubMed

41.

Ylikorkala O, Cacciatore B, Halonen K, Lassila R, Lammintausta R, Rutanen EM, Heikkinen J, Komi J (2003) Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women. Menopause 10(5):440–447. DOI 10.1097/01.GME.0000063566.84134.98CrossRefPubMed

42.

Komi J, Heikkinen J, Rutanen EM, Halonen K, Lammintausta R, Ylikorkala O (2004) Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol 18(3):152–158CrossRefPubMed

43.

Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O (2003) Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 10(5):433–439. DOI 10.1097/01.GME.0000063609.62485.27CrossRefPubMed

44.

Komi J, Lankinen KS, Harkonen P, DeGregorio MW, Voipio S, Kivinen S, Tuimala R, Vihtamaki T, Vihko K, Ylikorkala O, Erkkola R (2005) Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause 12(2):202–209CrossRefPubMed

45.

Komi J, Lankinen KS, DeGregorio M, Heikkinen J, Saarikoski S, Tuppurainen M, Halonen K, Lammintausta R, Vaananen K, Ylikorkala O, Erkkola R (2006) Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab 24(4):314–318. DOI 10.1007/s00774-006-0689-9CrossRefPubMed

46.

Bachmann GA, Komi JO, Ospemifene Study Group (2010) Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 17(3):480–486. DOI 10.1097/gme.0b013e3181c1ac01PubMed

47.

Portman DJ, Bachmann GA, Simon JA, Ospemifene Study Group (2013) Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 20(6):623–630. DOI 10.1097/gme.0b013e318279ba64PubMed

48.

Portman D, Palacios S, Nappi RE, Mueck AO (2014) Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas 78(2):91–98. DOI 10.1016/j.maturitas.2014.02.015CrossRefPubMed

49.

Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O, Ospemifene Study Group (2014) Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 17(2):173–182. DOI 10.3109/13697137.2013.834493CrossRefPubMedCentralPubMed

50.

Simon JA, Lin VH, Radovich C, Bachmann GA, Ospemifene Study Group (2012) One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. DOI 10.1097/gme.0b013e31826d36ba

51.

Simon J, Portman D, Mabey RG Jr, Ospemifene Study Group (2014) Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas 77(3):274–281. DOI 10.1016/j.maturitas.2013.12.005CrossRefPubMed

52.

Simon JA, Lin VH, Radovich C, Bachmann GA, Ospemifene Study Group (2013) One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 20(4):418–427. DOI 10.1097/gme.0b013e31826d36baPubMed

53.

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S, Women’s Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291(14):1701–1712. DOI 10.1001/jama.291.14.1701CrossRefPubMed

54.

Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinger M, Yood RA, Watts NB, Robbins JA, Lewis CE, Beresford SA, Ko MG, Naughton MJ, Satterfield S, Bassford T, Women’s Health Initiative Investigators (2006) Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women’s health initiative randomized trial. J Bone Miner Res 21(6):817–828. DOI 10.1359/jbmr.060312CrossRefPubMed

55.

Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB, Women’s Health Initiative Investigators (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290(13):1729–1738. DOI 10.1001/jama.290.13.1729CrossRefPubMed

Titel: Selektive Östrogenrezeptormodulatoren (SERM)
verfasst von: PD Dr. med. Petra Stute
Martin Birkhäuser
Publikationsdatum: 01.05.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Gynäkologische Endokrinologie / Ausgabe 2/2015
Print ISSN: 1610-2894
Elektronische ISSN: 1610-2908
DOI: https://doi.org/10.1007/s10304-015-0003-9

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Selektive Östrogenrezeptormodulatoren (SERM)

Zusammenfassung

Hintergrund

Indikationen

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie

Springer Medizin

Zusammenfassung

Hintergrund

Indikationen

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Hormonersatztherapie und Ovarialkarzinomrisiko

Mitteilungen der DMG

Akupunktur in der endokrinologischen Gynäkologie

Myome in der Schwangerschaft

MicroRNAs als Mediatoren des embryomaternalen Dialogs

Zusammenhang von Stress bei vergeblicher Kinderwunschbehandlung und Beziehungsstatus

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie